Gilead Sciences Inc (CHIX:GISd) Stock News, Headlines & Updates
Gilead Sciences Inc Stock News from GuruFocus
- 1
- 2
Jun 14, 2024
Gilead Sciences Inc's Dividend Analysis
GuruFocus Research • 5:01am
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
Business Wire • 3:00am
Jun 12, 2024
How Luciana Preger Is Helping Advance Gilead's Work in Oncology
ACCESSWIRE • 11:00am
Jun 06, 2024
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
Business Wire • 4:00am
Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis
ACCESSWIRE • 11:00pm
Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis
ACCESSWIRE • 7:00pm
Jun 05, 2024
Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis
ACCESSWIRE • 11:00am
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
Business Wire • 2:00am
Jun 03, 2024
Kite's Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Business Wire • 10:00am
Encouraging New Data Presented on Kite's Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
Business Wire • 9:00am
Jun 02, 2024
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
Business Wire • 8:00am
Jun 01, 2024
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
Business Wire • 8:00am
May 31, 2024
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
Business Wire • 8:00am
May 30, 2024
Gilead Provides Update on Phase 3 TROPiCS-04 Study
Business Wire • 4:00pm
May 29, 2024
Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot"
ACCESSWIRE • 11:00am
May 28, 2024
Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot"
ACCESSWIRE • 11:00am
May 22, 2024
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
Business Wire • 8:00am
May 21, 2024
Gilead Sciences Hosts Inaugural Global Health Equity Summit
ACCESSWIRE • 11:00am
May 18, 2024
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Business Wire • 8:00am
May 14, 2024
Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care
ACCESSWIRE • 11:00am
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
Business Wire • 10:00am
May 09, 2024
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Business Wire • 4:00pm
Gilead's FOCUS Program Helps Zero In on Early HIV Detection
ACCESSWIRE • 11:00am
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
GuruFocus Research • 11:07pm
May 07, 2024
Gilead Helps Put African Nation on Path To Eliminate Hepatitis C
ACCESSWIRE • 11:00am
May 03, 2024
Forbes Has Listed Gilead as One of America's Best Employers for Diversity
ACCESSWIRE • 3:00pm
Apr 30, 2024
Gilead Sciences to Present at Upcoming Investor Conferences
Business Wire • 4:00pm
Apr 26, 2024
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
Business Wire • 8:00am
Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and Strategic Insights
GuruFocus Research • 1:35am
Q1 2024 Gilead Sciences Inc Earnings Call Transcript
GuruFocus Research • 11:21pm
Apr 25, 2024
Gilead Sciences Inc (GILD) Q1 2024 Earnings: Misses Analyst EPS Estimates Amid Significant Acquisition Charges
GuruFocus Research • 3:41pm
Apr 18, 2024
Gilead Sciences Publishes 2023 ESG Impact Report
ACCESSWIRE • 3:00pm
Apr 08, 2024
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
Business Wire • 4:00pm
Apr 03, 2024
Insider Sell: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)
GuruFocus Research • 11:29pm
Apr 02, 2024
Gilead Sciences Champions Equal Pay
ACCESSWIRE • 11:00am
Mar 28, 2024
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
Business Wire • 8:00am
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
Business Wire • 7:00am
Mar 26, 2024
Winn Awards Help Physicians Solve Healthcare Disparities
ACCESSWIRE • 11:00am
Mar 25, 2024
Gilead Sciences Inc at Barclays Global Healthcare Conference Transcript
GuruFocus Research • 6:14pm
Gilead Sciences Inc at Leerink Partners Global Biopharma Conference Transcript
GuruFocus Research • 6:14pm
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news